Literature DB >> 11511425

Up-regulation of 'clearance' receptors in patients with chronic heart failure: a possible explanation for the resistance to biological effects of cardiac natriuretic hormones.

M G Andreassi1, S Del Ry, C Palmieri, A Clerico, A Biagini, D Giannessi.   

Abstract

BACKGROUND: Three specific receptors for the cardiac natriuretic peptide system have been identified to date. Down-regulation of the biologically active binding sites (i.e. NPR-A and NPR-B) could explain the blunted response to cardiac natriuretic hormones observed in heart failure (HF), but not the increased metabolic clearance rate. Variations in the ratio between biological and clearance (NPR-C) receptors in target tissue may explain this increase. AIM: The aim of this study was to investigate the regulation of NPR-C receptors on platelets, in patients with HF.
METHODS: Eighteen patients with HF (NYHA class: I-II, n=8; III-IV, n=10) and 18 age-matched healthy subjects were studied. The affinity constant (K(d)) and density (B(max)) of binding sites were derived by saturation assays on platelet suspensions using 125I-ANP as radioligand.
RESULTS: B(max) increased as a function of the severity of disease: 21.3+/-3.3 fmol/10(9) cells in class III-IV, 11.7+/-2.2 in class I-II, and 11.6+/-1.1 in controls, respectively (P=0.0179 for class III-IV vs. controls and P=0.0451 vs. NYHA I-II).
CONCLUSIONS: The increase in density of 'clearance' receptors in severe HF is theoretically consistent with the reduction in cardiac natriuretic peptide biological activity, as well as the increase in metabolic clearance rate. This suggests that clearance receptor blockade may be of potential therapeutic value in HF.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11511425     DOI: 10.1016/s1388-9842(01)00161-1

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  10 in total

Review 1.  Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure.

Authors:  Chaitanya Madamanchi; Hassan Alhosaini; Arihiro Sumida; Marschall S Runge
Journal:  Int J Cardiol       Date:  2014-08-09       Impact factor: 4.164

2.  Decompensated heart failure is associated with reduced corin levels and decreased cleavage of pro-atrial natriuretic peptide.

Authors:  Uzoma N Ibebuogu; Inna P Gladysheva; Aiilyan K Houng; Guy L Reed
Journal:  Circ Heart Fail       Date:  2011-01-07       Impact factor: 8.790

3.  Natriuretic peptides induce weak VASP phosphorylation at Serine 239 in platelets.

Authors:  Alessandra Borgognone; Kate L Lowe; Stephen P Watson; Melanie Madhani
Journal:  Platelets       Date:  2013-03-07       Impact factor: 3.862

4.  The cyclic guanosine monophosphate/B-type natriuretic peptide ratio and mortality in advanced heart failure.

Authors:  Patrícia Lourenço; José Paulo Araújo; Ana Azevedo; António Ferreira; Paulo Bettencourt
Journal:  Eur J Heart Fail       Date:  2009-02       Impact factor: 15.534

Review 5.  Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics.

Authors:  Emily J Tsai; David A Kass
Journal:  Pharmacol Ther       Date:  2009-03-21       Impact factor: 12.310

6.  C2238 ANP gene variant promotes increased platelet aggregation through the activation of Nox2 and the reduction of cAMP.

Authors:  Roberto Carnevale; Pasquale Pignatelli; Giacomo Frati; Cristina Nocella; Rosita Stanzione; Daniele Pastori; Simona Marchitti; Valentina Valenti; Maria Santulli; Emanuele Barbato; Teresa Strisciuglio; Leonardo Schirone; Carmine Vecchione; Francesco Violi; Massimo Volpe; Speranza Rubattu; Sebastiano Sciarretta
Journal:  Sci Rep       Date:  2017-06-19       Impact factor: 4.379

7.  Change in the NT-proBNP/Mature BNP Molar Ratio Precedes Worsening Renal Function in Patients With Acute Heart Failure: A Novel Predictor Candidate for Cardiorenal Syndrome.

Authors:  Hiroyuki Takahama; Toshio Nishikimi; Seiji Takashio; Tomohiro Hayashi; Chiaki Nagai-Okatani; Takashi Asada; Akihiro Fujiwara; Yasuaki Nakagawa; Masashi Amano; Yasuhiro Hamatani; Atsushi Okada; Makoto Amaki; Takuya Hasegawa; Hideaki Kanzaki; Kunihiro Nishimura; Satoshi Yasuda; Kenji Kangawa; Toshihisa Anzai; Naoto Minamino; Chisato Izumi
Journal:  J Am Heart Assoc       Date:  2019-08-23       Impact factor: 5.501

8.  Skeletal muscle derived Musclin protects the heart during pathological overload.

Authors:  Malgorzata Szaroszyk; Badder Kattih; Abel Martin-Garrido; Felix A Trogisch; Gesine M Dittrich; Andrea Grund; Aya Abouissa; Katja Derlin; Martin Meier; Tim Holler; Mortimer Korf-Klingebiel; Katharina Völker; Tania Garfias Macedo; Cristina Pablo Tortola; Michael Boschmann; Nora Huang; Natali Froese; Carolin Zwadlo; Mona Malek Mohammadi; Xiaojing Luo; Michael Wagner; Julio Cordero; Robert Geffers; Sandor Batkai; Thomas Thum; Nadja Bork; Viacheslav O Nikolaev; Oliver J Müller; Hugo A Katus; Ali El-Armouche; Theresia Kraft; Jochen Springer; Gergana Dobreva; Kai C Wollert; Jens Fielitz; Stephan von Haehling; Michaela Kuhn; Johann Bauersachs; Joerg Heineke
Journal:  Nat Commun       Date:  2022-01-10       Impact factor: 14.919

Review 9.  Atrial Natriuretic Peptide31-67: A Novel Therapeutic Factor for Cardiovascular Diseases.

Authors:  Gustavo Jose Justo da Silva; Raffaele Altara; George W Booz; Alessandro Cataliotti
Journal:  Front Physiol       Date:  2021-07-08       Impact factor: 4.566

10.  Combining patient proteomics and in vitro cardiomyocyte phenotype testing to identify potential mediators of heart failure with preserved ejection fraction.

Authors:  Roseanne Raphael; Diana Purushotham; Courtney Gastonguay; Marla A Chesnik; Wai-Meng Kwok; Hsiang-En Wu; Sanjiv J Shah; Shama P Mirza; Jennifer L Strande
Journal:  J Transl Med       Date:  2016-01-20       Impact factor: 5.531

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.